EUVIMEDEUVIMED entdecken
Crossref

Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia

Andrew D Sligar, Gretchen Howe, Julia Goldman, Patricia Felli, Almudena Gómez-Hernández, Eri Takematsu, Austin Veith, Shubh Desai, William J Riley, Rohan Singeetham, Lei Mei, Gregory Callahan und 3 weitere

Acta Biomaterialia · 2023

DOI: 10.1016/j.actbio.2023.06.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2023. Verfasst von Andrew D Sligar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Texas at Austin, 1 University Station, BME 5.202D, C0800, Austin, TX 78712, USA. Hauptthemen laut MEDLINE: Peripheral Vascular Diseases, Hyperlipidemias. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: CDMRP, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regenerative therapeutics for treating peripheral arterial disease are an appealing strategy for creating more durable solutions for limb ischemia. In this work, we performed preclinical testing of an injectable formulation of syndecan-4 proteoliposomes combined with growth factors as treatment for peripheral ischemia delivered in an alginate hydrogel. We tested this therapy in an advanced model of hindlimb ischemia in rabbits with diabetes and hyperlipidemia. Our studies demonstrate enhancement in vascularity and new blood vessel growth with treatment with syndecan-4 proteoliposomes in combination with FGF-2 or FGF-2/PDGF-BB. The effects of the treatments were particularly effective in enhancing vascularity in the lower limb with a 2-4 increase in blood vessels in the treatment group in comparison to the control group. In addition, we demonstrate that the syndecan-4 proteoliposomes have stability for at least 28 days when stored at 4°C to allow transport and use in the hospital environment. In addition, we performed toxicity studies in the mice and found no toxic effects even when injected at high concentration. Overall, our studies support that syndecan-4 proteoliposomes markedly enhance the therapeutic potential of growth factors in the context of disease and may be promising therapeutics for inducing vascular regeneration in peripheral ischemia. STATEMENT OF SIGNIFICANCE: Peripheral ischemia is a common condition in which there is a lack of blood flow to the lower limbs. This condition can lead to pain while walking and, in severe cases, critical limb ischemia and limb loss. In this study, we demonstrate the safety and efficacy of a novel injectable therapy for enhancing revascularization in peripheral ischemia using an advanced large animal model of peripheral vascular disease using rabbits with hyperlipidemia and diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Vascular DiseasesHyperlipidemiasRabbitsMiceAnimalsSyndecan-4Fibroblast Growth Factor 2Neovascularization, PhysiologicIschemiaHindlimbDisease Models, AnimalProteolipids

Stichwörter der Autor:innen

AlginateCritical limb ischemiaFibroblast growth factor-2Intermittent claudicationPeripheral ischemiaPeripheral vascular diseasePlatelet derived growth factor-BBRevascularizationSyndecan-4 proteoliposomesTherapeutic angiogenesis

Substanzen

Syndecan-4Fibroblast Growth Factor 2proteoliposomesProteolipids

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Texas at Austin, 1 University Station, BME 5.202D, C0800, Austin, TX 78712, USA.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, University of Texas Medical School at Houston, TX, USA.
  • Center for Laboratory Animal Medicine and Care, UT Health Science Center at Houston, USA.
  • Department of Biochemistry and Molecular Biology, School of Pharmacy, Complutense University of Madrid, Madrid, Spain.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, University of Texas Medical School at Houston, TX, USA; Memorial Hermann Heart and Vascular Institute, Houston, TX, USA.
  • Department of Biomedical Engineering, University of Texas at Austin, 1 University Station, BME 5.202D, C0800, Austin, TX 78712, USA; Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, T…

Förderung

  • CDMRP
  • National Institutes of Health

Zitieren

APA

Sligar, A. D., Howe, G., Goldman, J., Felli, P., Gómez-Hernández, A., Takematsu, E., Veith, A., Desai, S., Riley, W. J., Singeetham, R., Mei, L., Callahan, G., Ashirov, D., Smalling, R., & Baker, A. B. (2023). Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2023.06.006

Vancouver

Sligar AD, Howe G, Goldman J, Felli P, Gómez-Hernández A, Takematsu E, et al. Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia. Acta Biomaterialia. 2023. doi:10.1016/j.actbio.2023.06.006

BibTeX
@article{Sligar2023,
  author = {Sligar, Andrew D and Howe, Gretchen and Goldman, Julia and Felli, Patricia and Gómez-Hernández, Almudena and Takematsu, Eri and Veith, Austin and Desai, Shubh and Riley, William J and Singeetham, Rohan and Mei, Lei and Callahan, Gregory and Ashirov, David and Smalling, Richard and Baker, Aaron B},
  title = {Syndecan-4 proteoliposomes enhance revascularization in a rabbit hind limb ischemia model of peripheral ischemia},
  journal = {Acta Biomaterialia},
  year = {2023},
  doi = {10.1016/j.actbio.2023.06.006}
}
Kostenlos starten →